About HitGen

2023

DNA Encoded Library Size: >1.2 Trillion

Jan

HitGen won the award of "The Biopharmas with Most Growth Potential" in the selection of "The 12th Reputation List of China Listed Companies in 2022" sponsored by National Business Daily, one of the most influential business media in China.
Feb

HitGen was selected as one of the “Top 100 New Economy Enterprises in Sichuan in 2022” by Sichuan Institute of Industry and Information Technology.
Mar

HitGen held a ceremony to celebrate its tenth anniversary of establishment and third anniversary of being listed on Shanghai Stock Exchange.
Mar

HitGen held a press conference on the future development of nucleic acid drug. At the event, HitGen and Easton Biopharmaceuticals jointly announced the establishment of Hitston.
Mar

Mr. Wenhui CHENG, Vice Chairman of the National Council for Social Security Fund, led a delegation to visit HitGen Inc.
Apr

HitGen announced its FY2022 Annual Report: the continued development of core DEL platform as well as the emerging FBDD/SBDD, STO and TPD platforms underpin the company’s long-term growth.
May

HitGen announced drug discovery research agreement with ARase Therapeutics.
Jun

HitGen openDEL™ Self-Service Screening Kit is newly upgraded!
Jun

HitGen ranked in 2022 China CXO enterprises top20.
Jul

HitGen released DEL For series of services.
Aug

HitGen Enters into DNA-Encoded Library Based Research Service Agreement with Nested Therapeutics.
Aug

HitGen announced its 2023 Semi-annual Report：Core business has gradually recovered, and business expansion has achieved significant results.
Sep

Pierre Fabre Laboratories and Vernalis announce a drug discovery collaboration in oncology.
Sep

SGC and HitGen Announce Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery.
Oct

Dr. Jin Li led a delegation to visit Peking University Chengdu Academy for Advanced Interdisciplinary Studies.
Oct

Venture forces invest millions in new type of treatment for particularly aggressive form of cancer.
Nov

HitGen’s Holding Subsidiary Hitston, officially put into production.
Dec

Saudi Investment Minister His Excellency Khalid A. Al-Falih Meets with Dr. Li Jin of HitGen in Beijing

2022

DNA Encoded Library Size: >1.2 Trillion

Jan

The IND application of innovative anti-tumor drug HG030 of HitGen was approved by FDA
Apr

HitGen and the PACS1 Syndrome Research Foundation announce an agreement to discover ligands that address issues related to the mutated PACS1 gence product.
May

HitGen Announces Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery.
Jun

HitGen obtained ISO27001 certification, its information security management capability was internationally recognized.
Jun

HitGen launched OpenDEL®3.0, which is a new upgrade product for Open access.
Dec

Recognized as a "CAS Registry® Innovator".
PROTAC molecule discovery and optimization strategy and case study on ACS Chemical Biology and selected as an "ACS Editors Choice".

2021

DNA Encoded Library Size: >1 Trillion

Mar

HitGen’s New Generation of NTRK/ROS1 Inhibitor HG030 Approved for Clinical Trial.
Apr

HitGen received approval to be listed on the Shanghai Stock Exchange.Stock code：HitGen 688222.SH
May

The company and Tasly signed an innovative drug development alliance to jointly commit to the research and development of innovative drugs in China, and strengthen our determination to start the domestic cycle;
Jun

The company and Tasly signed an innovative drug development alliance to jointly commit to the research and development of innovative drugs in China, and strengthen our determination to start the domestic cycle;
Aug

HitGen was recognized as a 2019 top innovator among Asia-Pacific pharmaceutical companies by Cortellis
Oct

Held 2019 International Symposium on the Frontiers and Practice of Innovative Drug with more than 1200 attendees
Dec

HitGen was recognized as China Best Employer Award 2019 - China Most Aspiring Employers in Chengdu by Zhilian

2020

DNA Encoded Library Size: 1 Trillion

Mar

HitGen’s New Generation of NTRK/ROS1 Inhibitor HG030 Approved for Clinical Trial.
Apr

HitGen received approval to be listed on the Shanghai Stock Exchange.Stock code：HitGen 688222.SH
May

The company and Tasly signed an innovative drug development alliance to jointly commit to the research and development of innovative drugs in China, and strengthen our determination to start the domestic cycle;
Jun

The company and Tasly signed an innovative drug development alliance to jointly commit to the research and development of innovative drugs in China, and strengthen our determination to start the domestic cycle;

2019

DNA Encoded Library Size: >400 billion

Jul

HitGen was awarded of 2018 CRO top 20 enterprises in China

2018

DNA Encoded Library Size: >300 billion

May

HitGen's Small Molecule IND HG146 Receives Approval by National Medical Products Administration for Clinical Trials.
Completion of RMB 250 Million Series B Fund Raising
Jul

Dr. Jin Li received the Award of Honorary Doctor of Science from Aston University, UK
Oct

Held 2018 International Symposium on Frontiers and Practice of Innovative Drug Discovery and The 8th International Symposium on DNA-Encoded Chemical Libraries, which was the first time that the DNA-Encoded Chemical Libraries Conference was held in Chengdu, China. Previously it was held annually in Zurich or Boston, and from now on it will be held alternately in Zurich, Boston and Chengdu
Nov

BioCentury Innovations published cover report: HitGen's DNA for Small Molecules
Dec

HitGen moved into its new offices at Tianfu International Bio-Town, Chengdu

2017

DNA Encoded Library Size: >85 billion

Jul

HitGen is mentioned in Nature: (Chinese Biopharma Starts Feeding the Global Pipeline)

2016

DNA Encoded Library Size: 8 billion

Apr

HitGen, as a "high-tech pioneer" of biotechnology field in China, was inspected and encouraged by Premier Li Keqiang.
Professor Richard Lerner and Professor Barry Sharpless visited HitGen.
May

Nature BioTechnology published an article "DNA-Encoded Drug Libraries Come of Age" and gave recognition of contribution in innovative drug discoveries area of HitGen and other DEL companies worldwide
Jul

HitGen Pharmaceuticals Inc. (a subsidiary of HitGen) was founded
Nov

Held 2016 International Summit on Frontiers and Practice of Innovative Drug Discovery in Chengdu, China.
HitGen was recognized as "National Hi-Tech Enterprise" by Ministry of Science and Technology of The People's Republic of China
Dec

HitGen was recognized as "Sichuan Engineering Research Center for Screening of Lead Compounds" by Science & Technology Department of Sichuan Province

2015

DNA Encoded Library Size: 4.2 billion

Jan

HitGen was recognized as "Sichuan Postdoctoral Innovation Practice Base" by Sichuan Provincial Human Resources and Social Security Department.
Dr. Jin Li won "Sichuan Outstanding Contributions of Outstanding Experts" from Sichuan Provincial Party Committee.
Oct

The core patents granted: ZL201210555548.3 ZL201210555088.4

2014

DNA Encoded Library Size: 1.3 billion

Sep

Dr. Jin Li won "Overseas Chinese Returnees Contribution Award" from All-China Federation of Returned Overseas Chinese
Dec

HitGen won "Leading Innovative and Entrepreneurial" from The Organization Department of The Sichuan Provincial Municipal Party Committee

2013

DNA Encoded Library Size: 300 million

Oct

Dr. Jin Li became "Fellow of the Royal Society of Chemistry"

Held 2nd International Symposium on Lead Generation Technology and Industry Development
Dec

HitGen won "Chengdu Talents Plan Top Team" from The Organization Department of The Chengdu Municipal Party Committee

2012

Establishment of HitGen

Feb

HitGen Ltd., based in Chengdu, P. R. China, aiming to discover and develop innovative drugs based on its core platform of DNA Encoded Libraries (DELs)
Dec

Held 1st International Symposium on Lead Generation Technology and Industry Development

HitGen Inc.

History and Honor

Publications

Download Center

Thanks for reading!